M ost patients who undergo resection for pancreatic adenocarcinoma (PDAC) ultimately develop local recurrence or distant metastasis that are largely attributed to occult disease not detected during preoperative staging or surgery. 1 These cells and nuclear material can be detected in the blood as circulating tumor cells (CTCs) or cell-free DNA (cfDNA) as a means of "liquid biopsy," and we refer to their presence as tumoremia. 2 CTCs are intact, often viable cells that can be isolated from normal blood cells based on their disparate physical and chemical properties, and cell surface molecules. cfDNA is isolated from plasma or serum and includes nontumor and tumor DNA. 3 Tumor-derived cfDNA is referred to as circulating tumor DNA (ctDNA) and is the component from which genetic alterations such as KRAS mutations are identified.
Preliminary evidence indicates that tumoremia is precipitated by tumor manipulation during biopsy or surgery, which is a concern given the potential for hematogenous dissemination and distant metastasis. [4] [5] [6] [7] [8] We tested the hypothesis that for treatment-naïve PDAC patients, primary tumor endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) induces tumoremia. We determined the peripheral blood plasma cfDNA concentration and detected ctDNA by KRAS 12/13 mutational analysis using digital droplet polymerase chain reaction (PCR). KRAS is an ideal biomarker, as >90% of PDACs harbor KRAS 12/13 mutations, 9 which we refer to as ctDNA-mutant detectable to distinguish it from ctDNA nondetectable.
Our primary aims were to determine: (1) the incidence of FNA-induced tumoremia, defined by !2-fold increase in total cfDNA concentration, or conversion from ctDNA mutant nondetectable to detectable; and (2) the feasibility and safety of serial portal vein (PV) and hepatic vein (HV) blood collections. Secondary aims were to determine: (1) the primary tumor and peripheral blood ctDNA-mutant concordance rate; and (2) the difference in peripheral vein, PV, and HV cfDNA and ctDNAmutant concentrations as pilot data for future studies.
Materials and Methods
The study was approved by the Institutional Review Board (#14-009985) and written informed consent was obtained. Enrollment criteria included: (1) referral for EUS-FNA of a suspected PDAC; (2) telecytology confirmation of PDAC; and (3) treatment-naïve disease. Exclusion criteria included: (1) anemia (hemoglobin <12.4 g/dL for men and <11.6 g/dL for women); (2) pregnancy; (3) <18 years of age; or (4) intervening structures prohibiting needle access.
EUS Examination, Staging FNA, and Blood Collection
EUS was performed (GF-UCT180; Olympus Medical Systems, Center Valley, PA) for PDAC biopsy and staging.
Blood was collected before EUS-FNA (designated pre-FNA), obtaining 10 mL from 3 sites (peripheral vein, PV, HV) using a 22-gauge needle (Wilson Cook, WinstonSalem, NC) after discarding 5 mL for each blood draw. HV blood was obtained via the stomach in each patient. PV blood was obtained via the duodenum in 8 patients vs stomach in 2 patients due to the absence of a suitable transduodenal window. Primary tumor FNA was performed until the specimens were interpreted as positive for adenocarcinoma by telecytology confirmation. Thereafter, blood was collected (post-FNA specimens) from the same 3 vascular sites within 15 minutes of the final FNA. All peripheral (n ¼ 35 patients) and the initial PV and HV (n ¼ 10 patients) blood was collected in 10-mL Streck Cell-Free DNA BCT tubes (Streck, Omaha, NE). Although 10 patients underwent PV and HV EUS-FNA with measurable cfDNA levels in each, the molecular status was determined in 5 patients due to an alteration in technique that impaired the analysis. Blood aspiration was slower from central blood, and we altered our technique for the last 5 patients by adding 2 mL of heparin (10,000 USP) to Streck tubes, which interfered with KRAS testing.
Patients were monitored during the procedure and in postoperative recovery, seen in clinical follow-up within 7 days, and contacted by telephone 15-30 days later to assess adverse events. Medical records were reviewed, and when necessary telephone follow-up, was conducted 2-4 months later to identify delayed adverse events. All patients were seen in clinical follow-up within 7 days, during which time we would anticipate detecting most procedural-related adverse events. Two subsequent assessments were implemented to identify delayed events, that of detected mandated clinical follow-up. Post-EUS FNA imaging (computed tomography, magnetic resonance imaging, and positron emission tomography) and interventions with biopsy were reviewed to identify new distant metastasis (eg, liver, lung, and bone) to assess the potential impact of tumoremia. Local tumor spread and lymphadenopathy were not considered indicative of possible tumor-induced metastasis.
Control Group
For clinical laboratory quality assurance purposes, our patient control group comprised 69 healthy donors undergoing routine or preventive clinical care without known or suspected cancer and each evaluated for peripheral blood plasma cfDNA concentration levels and cfDNA KRAS 12/13 mutation testing.
Cytology, cfDNA and ctDNA Processing and Evaluation
Standard techniques were used for cytology, cfDNA, and ctDNA specimen handling, processing, and evaluation (Supplementary Appendix 1). 
Statistical Analysis

Adverse Events
Based on intraprocedural and postoperative monitoring, clinical (within 7 days) and telephone follow-up (at 15-30 days), and chart review or telephone followup (at 2-4 months), no patient developed evidence of hemorrhage. One patient each developed mild abdominal pain and mild acute pancreatitis.
Total cfDNA Concentration
The median peripheral blood plasma cfDNA concentration displayed a nonsignificant increase following primary tumor FNA (1200 [500-3300] ng/mL vs 1400 [900-4000] ng/mL; P ¼ .391) ( Table 2 , Figures 1 and 2 ). The median PV blood plasma cfDNA concentration displayed a nonsignificant increase following primary tumor FNA (1100 [430-3210] ng/mL vs 1300 [320-3010] ng/mL; P ¼ .853). While the increase in median HV blood plasma concentration was not statistically significant (630 [428-4100] ng/mL vs 2730 [260-4680] ng/mL; P ¼ .571), the markedly discrepant concentrations suggest that the lack of statistical significant may be due the limited sample size.
The peripheral blood cfDNA concentration pre-FNA was significantly higher for PDAC patients than for control subjects (1200 [500-3300] ng/mL vs 600 [475-825] ng/mL; P ¼ .0013). Based on ROC analysis, the pre-FNA cfDNA concentration cutoff of >1100 ng/mL provided a sensitivity and specificity for malignancy of 54.3% and 92.8%, respectively (area under the curve, 0.693; 95% confidence interval, 0.595-0.780; P ¼ .0038).
Peripheral Blood ctDNA-Mutant Status
Plasma ctDNA mutants were detected in the peripheral blood in 11 (31.4%) patients ( Figure 3 ). Within this cohort, 6 of 11 (54.5%) patients had a ctDNA mutant detected in the pre-and post-FNA peripheral blood, whereas the other 5 patients had a ctDNA mutant detected only within their pre-FNA (n ¼ 2) or post-FNA (n ¼ 3) specimens, but not both. ctDNA-mutant was not detected in the remaining 24 (68.6%) patients. ROC analysis highlighted that a pre-FNA cfDNA cutoff of >5800 ng/mL yielded a sensitivity and specificity to detect a ctDNA mutant of 36.4% and 100%, (area under the curve, 0.54; 95% confidence interval, 0.364-0.709; P ¼ .775), respectively. Only 1 of 69 (1.4%) healthy control subjects had 1 droplet positive for KRAS at 3 copies/mL plasma (median mutant copy number 0.04 copies/mL).
EUS-Induced Tumoremia
Based on predefined metrics, either a !2-fold increase in total cfDNA concentration (n ¼ 7; 20.6%), or conversion from ctDNA-mutant nondetectable to detectable (n ¼ 3; 8.8%), primary tumor FNA-induced tumoremia occurred in 10 of 35 (28.6%) patients. Tumoremia (n ¼ 10) and nontumoremia (n ¼ 25) groups were similar in terms of baseline tumor stage, CA 19-9 and blood glucose levels, and the number undergoing subsequent resection and chemoradiotherapy (Table 3) . Tumoremia patients had a greater likelihood (1.3 AE 0.82 
Primary Tumor and Peripheral Blood KRAS Mutant Concordance
While primary tumor KRAS mutants were identified in 32 of 34 (94%) patients, matched peripheral blood (pre-or post-FNA) samples were positive in only 10 of 32 (31.3%) patients. For the 2 patients with primary tumor KRAS-nondetectable status, the peripheral blood was mutant positive and negative in 1 patient each. The peripheral blood and primary tumor KRAS 12/13 concordance rate was 11 of 34 (32.4%), with a sensitivity and specificity of 31.3% and 50%, respectively.
Discussion
PDAC patients have a dismal prognosis that is largely attributed to the aggressive tumor biology, infrequent symptoms, and occult dissemination of tumor cells. 10 EUS-FNA plays a central role in diagnosis and staging. However, it is neither practical nor cost effective to perform serial EUS-FNA, which has driven the pursuit for more accurate and less invasive approaches, including liquid biopsy. The choice of CTC vs cfDNA depends on the intended use and scientific questions. 11, 12 CTCs are functionally intact cells that may provide a specific cancer diagnosis and facilitate biological and mechanistic studies. 13 The utility is limited by the rarity of these cells in the circulation.
14 cfDNA testing offers simple processing and analysis, capability of prolonged storage and batched processing, correlation with clinical and tumor characteristics, and mutation assessment to guide individualized care. 3, 11 However, the cfDNA concentration cannot accurately diagnose PDAC due to the varied sources of DNA, and specific mutations must be identified to establish the tumor origin. 3, 12 Based on the relative strengths and limitations, we used cfDNA/ctDNA mutant identification in preference to CTC testing to determine the risk of EUS-FNA-induced tumoremia. Limited data suggest that surgery precipitates tumoremia, as shown in 40 patients with pancreaticobiliary cancer. 15 Blood was collected from the PV, superior vena cava, and peripheral artery before and during resection and tested using cardioembryonic antigen real-time PCR. carcinoembryonic antigen-messenger RNA expression was found in 42% of patients with biliary cancer, 62% with PDAC, but none of the healthy volunteers or patients with benign disease. The first set of PV, superior vena cava, and peripheral artery samples were positive in 8%, 9%, and 8% of patients, compared with postresection values of 23%, 26%, and 30%, which was significant for all 3 vessels. Another study involving 12 PDAC patients compared no-touch isolation surgery (n ¼ 6) to standard pancreaticoduodenectomy (n ¼ 6), to determine the impact on CTC counts and risk of tumoremia as analyzed by bead-based fluorescence CellSearch system (Veridex, Raritan, NJ). 6 CTCs were measured from PV blood obtained before and following resection. CTCs increased in 83% following standard resection vs no patient following no-touch isolation surgery. The potential for surgery-induced tumoremia has also been demonstrated for lung, hepatocellular, esophageal, gastric, colorectal, renal, and prostate cancer. 4, 7, 8 Studies highlight the risk of biopsy-induced tumoremia as demonstrated in 23 prostate cancer patients. 5 They evaluated epithelial cellular material (ECM) based on anticytokeratin antibody anti-CD45 and DAPI. ECM was present in the peripheral blood 39% of cancer patients prebiopsy vs 7% of control subjects. In contrast, ECM was detected after core needle biopsy in 83% of cancer patients vs 13% of control subjects. There was a significant increase in peripheral blood ECM in 61% of cancer patients. In our study, FNA-induced tumoremia developed in 28.6% of patients. We liken this to endoscopy-induced bacteremia. 16 Tumoremia induced .7000 Second site (sites) NOTE. Values are presented as n/n (%), mean AE SD, or median (interquartile range), unless otherwise indicated. EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
a New metastatic sites include distant organs (eg, liver, lung, skeletal) and do not include nodal metastasis or direct local infiltration. Excludes patients in whom follow-up imaging was not obtained.
by surgery or EUS is potentially concerning due to the potential for tumor recurrence or metastasis. Our followup data demonstrate that despite similarities in baseline markers of disease severity and similar use of surgery and chemoradiation, tumoremia patients had a greater likelihood of developing new distant metastasis that tended to occur sooner after EUS FNA. While the overall survival was similar for deceased tumoremia and nontumoremia patients, all 6 surviving patients are within the nontumoremia group and they remain alive a median of 23.9 months following EUS FNA. In contrast, all tumoremia patients have succumbed to their disease. Healthy control subjects typically have plasma cfDNA levels of 6-100 ng/mL, [17] [18] [19] vs cancer patients with values >100 ng/mL. 20, 21 However, there is no broadly accepted concentration that distinguishes cancer patients. In our study, the median peripheral blood cfDNA concentration was significantly higher for PDAC patients vs healthy control subjects suggesting the potential diagnostic utility. ROC determined that a pre-FNA cfDNA cutoff of >1100 ng/mL provided a significant yet clinically suboptimal sensitivity and specificity for malignancy of 54.3% and 92.8%, respectively. While cfDNA levels increase !2-fold based on the number of major arteries or veins infiltrated suggesting a cohort susceptible to tumoremia, more data are needed to verify this correlation.
KRAS is the optimal target for ctDNA testing in PDAC given the >90% occurrence within primary tumors and early presence in tumorigenesis, 22 although detection is considerably lower in blood 2, [23] [24] [25] and reported concordance rates vary from 0% to 90%. 24, 26 Our composite peripheral blood ctDNA-KRAS mutant test sensitivity of 31.3% suggests this is a poor surrogate for PDAC diagnosis. This limitation is highlighted when considering composite testing that allowed either pre-and post-FNA sample positivity to be considered a positive result. The independent pre-and post-FNA samples provided a sensitivity of 22% and 25%, respectively. This suggests that repeated sampling may improve test sensitivity, but issues of expense and practicality must be considered.
PV and HV blood were collected for feasibility and safety data, as these sites may improve our understanding of the tumoremia risk, mechanisms of DNA clearance, and tumor-specific propensity for site-specific metastasis. Discrepancies between peripheral and PV blood testing were reported by Bissolati et al, 27 who evaluated 20 PDAC patients, demonstrating that patients with CTCs in PV blood had higher hepatic metastasis rates. 27 Our experience in 10 patients who underwent PV and HV FNA before, and following tumor FNA (40 samples) suggests the safety of EUS-guided central blood collection. However, problems encountered using a 22-gauge needle suggest the need to use larger caliber needles or anticoagulants that do not impair molecular analysis. Catenacci et al 28 reported the safety and feasibility of EUS-guided PV blood collection in 18 patients with pancreaticobiliary cancers. 28 Using a 19-gauge needle, they demonstrated higher CTC detection of 100% vs 22% for PV and peripheral blood, respectively, and a greater number of CTCs of 118.4 AE 36.8 vs 0.8 AE 0.4 CTCs in peripheral blood (P < .01). Further investigation is needed to determine the clinical utility and role of peripheral vs central blood evaluation.
Our study strengths include molecular testing of treatment-naïve patients with varying disease stages; having a large control group; being the first study to evaluate peripheral, PV, and HV blood; confirmatory primary tumor KRAS testing; combined cfDNA concentration analysis and multiplex KRAS PCR that covered >99% of PDAC KRAS hotspots; and being the first study to evaluate the risk of FNA-induced tumoremia. Study limitations include the use of cfDNA and ctDNA-mutant testing as markers of tumoremia that, although intuitively logical, may not be the optimal criteria. We recognize that changes in cfDNA concentration or conversion from ctDNA nondetectable to ctDNA detectable may reflect normal temporal fluctuations despite data suggesting tight test reproducibility and limited natural fluctuation. 29 Also, changes in cfDNA concentration may reflect deposition of nontumor fragments from desmoplastic or inflammatory tumor components. Our low rate of cfDNA-mutant detection (11 of 35) in the blood, while in keeping with other studies, highlights the potential utility of such testing, but also the limited utility when used as a means of liquid biopsy. Furthermore, the inconsistent detection in the 2 samples may reflect tumoremia or issues with the precision of the assays.
While we utilized digital droplet PCR due to greater test sensitivity that best met the study goals, other technologies such as CTC testing and next-generation sequencing may also be of use. There are advantages and disadvantages of each molecular platform, without evidence of a clear advantage for all purposes. The choice largely depends on the scientific and clinical questions being asked. We considered each of these technologies that are all available to us, and felt that the techniques we adopted best suit our study goals. Studies may demonstrate that combining technologies in the same patient best addresses the myriad of questions. However, doing so greatly increases the cost and amount of blood that must be obtained. Finally, the presence of tumoremia does not necessarily translate into eventual occurrence of clinically significant metastatic disease because tumor cells and nuclear material are rapidly destroyed in the blood and the process of metastasis is an ineffective process. On first glance, our data suggest that we may be increasing risk of metastases in many patients with PDAC; however, the findings should be regarded as preliminary and do not suggest current need to modify standard practice.
Conclusions
Our data suggest that primary tumor FNA may release nuclear material or cells into the circulation. Our data, although highly suggestive, are preliminary and do not definitively indicate a heightened risk of FNAinduced tumoremia, resulting negative impact on patient outcome, or current need to alter standard clinical practice. Studies are needed to confirm our results and to assess the impact on patient outcome, establish the benefit of quantitative and qualitative cfDNA-ctDNA testing, and clarify the utility of sampling central blood. PDAC patients lack personalized treatment options due to the absence of effective targeted therapies and because tumor biopsy provides incomplete molecular characterization. While liquid biopsy may overcome these limitations, our data suggest that cfDNA testing for KRAS mutations cannot replace tumor biopsy for diagnosis or consistently detect actionable mutations for individualized patient care. Nevertheless, the tremendous promise is sure to drive additional study, for which EUS is likely to play a key role.
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